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Abstract
 Design—Persistent latently infected CD4+ T cells represent a major obstacle to HIV 
eradication. Histone deacetylase inhibitors (HDACis) are a proposed activation therapy. However, 
off-target effects on expression in host immune cells are poorly understood. We hypothesized that 
HDACi-modulated genes would be best identified with dose-response analysis.
 Methods—Resting primary CD4+ T cells were treated with 0.34, 1, 3, or 10 μM of the 
HDACi, SAHA, for 24 hours and subjected to microarray gene expression analysis. Genes with 
dose-correlated expression were filtered to identify a subset with consistent up or downregulation 
at each SAHA dose. Histone modifications were characterized in 6 SAHA dose-responsive genes 
by chromatin immunoprecipitation (ChIP-RT-qPCR).
 Results—A large number of genes were shown to be up (N=657) or downregulated (N=725) 
by SAHA in a dose-responsive manner (FDR p-value < 0.05, fold change ≥ |2|). Several genes 
(CTNNAL1, DPEP2, H1F0, IRGM, PHF15, and SELL) are potential in vivo biomarkers of SAHA 
activity. SAHA dose-responsive genes included transcription factors, HIV restriction factors, 
histone methyltransferases, and host proteins that interact with HIV. Pathway analysis suggested 
net downregulation of T cell activation with increasing SAHA dose. Histone acetylation was not 
correlated with host gene expression, but plausible alternative mechanisms for SAHA-modulated 
gene expression were identified.
 Conclusions—Numerous genes in CD4+ T cells are modulated by SAHA in a dose-
responsive manner, including genes that may negatively influence HIV activation from latency. 
Our study suggests that SAHA influences gene expression through a confluence of several 
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mechanisms, including histone modification, and altered expression and activity of transcription 
factors.
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 Introduction
The unsolved challenge for HIV treatment is to eradicate persistent latent reservoirs in 
infected individuals maintained on combination antiretroviral therapy (ART). “Shock and 
Kill” approaches have been proposed as cure strategies for HIV[1]. Treatment with drugs 
that activate HIV out of latency (shock), combined with continued ART to prevent the 
spread of infection, may allow the host immune system to eliminate latently infected cells 
(kill)[2]. Numerous drugs have been proposed to provide the shock in a shock and kill 
strategy towards an HIV cure, including: histone deacetylase inhibitors (HDACis), Protein 
Kinase C agonists (e.g., Ingenol derivatives and Bryostatin), Bromodomain inhibitors (e.g., 
JQ1), among others[3]. HDACis have been the most scrutinized class of compounds and 
includes suberoylanilide hydroxamic acid (SAHA, also known as vorinostat), which is 
approved by the FDA for the treatment of cutaneous T cell lymphoma[4].
The ability of SAHA to activate HIV has been assessed in two separate clinical trials 
(ClinicalTrials.gov registry numbers NCT01319383 and NCT01365065) with several others 
currently recruiting (NCT02475915, NCT02336074 and NCT01249443). Analysis of data 
from the completed trials indicates that SAHA induces the production of cell associated HIV 
RNA in the vast majority HIV-infected subjects but activation of HIV varies from donor to 
donor, and a concurrent increase in plasma HIV RNA associated with virions is difficult to 
detect[5–7]. Encouragingly, two other HDACis, panobinostat and romidepsin, may have 
greater potency for activating HIV[8, 9], and are currently being assessed in clinical trials 
(NCT01933594 and NCT01680094, respectively).
However, the off-target effects of these compounds are even less understood than for SAHA. 
Therefore, the full extent of SAHA’s clinical utility in a shock and kill strategy remains to 
be evaluated. Current clinical trials assess shock compounds in isolation and future studies 
are required to assess compounds in combinations. Due to SAHA’s ability to activate HIV 
transcription, it is plausible that SAHA will be included in future combination therapies in 
conjunction with compounds that can relieve the inhibition that is restricting virion 
production[7].
HDACis cause hyperacetylation of histones by preventing deacetylation, leading to 
chromatin unwinding and recruitment of transcriptional machinery[10]. HIV transcription is 
thought to occur at least partly through this mechanism at sites where HIV is integrated in 
the host genome, but activation may also involve non-histone targets, and is not yet fully 
understood[11]. It has been hypothesized that HDACis alter the expression of host genes that 
influence HIV activation, but the identities of these host genes are largely unknown[11]. The 
non-specific nature of histone acetylation suggests that widespread effects on host gene 
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expression are likely to occur, so it is also important to investigate the potential for off-target 
side effects of SAHA in immunocompromised patients. Furthermore, the optimal dosing 
regimen for SAHA has not yet been determined for HIV patients. The currently 
recommended oral dose of 400 mg, once daily, results in a peak serum concentration of 1.2 
μM[4]. Intravenous dosing results in peak serum concentration of 9.1 μM, and was 
surprisingly better tolerated than oral dosing in clinical trials for cancer[12].
Our laboratory previously reported minimal off-target effects on host gene expression for 
primary CD4+ T cells treated for 24 hours with 0.34 μM SAHA[13]. Only 37 of 1880 
significantly modulated genes had expression changes above 2-fold. However, SAHA-
modulated gene expression has not previously been examined over the entire concentration 
range relevant to HIV cure strategies. Our goal was to identify SAHA dose-responsive genes 
that could be used as in vivo biomarkers of SAHA activity. Primary CD4+ T cells were 
treated with 0.34, 1, 3, or 10 μM of SAHA. Genes consistently up or downregulated in a 
dose-dependent manner were identified. Host cell functions affected by these genes may 
have implications for the efficacy and safety of therapies for both HIV and cancer.
 Methods
 Isolation of primary CD4+ T cells
Human peripheral blood was drawn according to institutional review board approved 
protocols from 9 healthy HIV-seronegative donors by venipuncture and collected into 
sodium heparin containing tubes. Peripheral blood mononuclear cells (PBMCs) were 
collected from fresh whole blood by centrifugation. Primary CD4+ T cells were isolated 
from PBMCs with RosetteSep CD4+ Isolation Kits according to manufacturer protocol 
(Stem Cell Technologies). CD4+ T cells were incubated at 37°C, 5% CO2 overnight in 
RPMI-1640 with 5% human serum AB. CD4+ T cell purity and activation were assessed 
with flow cytometry. All samples included in microarray analysis had >95% purity with 
fewer than 10% activated cells (i.e., <10% expressing HLA-DR).
 SAHA treatment of primary CD4+ T cells
CD4+ T cells were aliquoted into 6-well plates; 5 million cells per well in 2 mL of media 
(RPMI-1640 with 5% human serum AB). These cells were treated with 0.34 μM, 1 μM, 3 
μM, or 10 μM SAHA (Merck) in 0.1% DMSO, or with only 0.1% DMSO, and incubated at 
37°C, 5% CO2 for 24 hours.
 Microarray analysis of gene expression
RNA was extracted from treated cells using Qiagen RNeasy kits according to manufacturer 
protocol. RNA integrity numbers (RINs) were determined with the Agilent 2100 
Bioanalyzer (Agilent Technologies). RNA samples submitted for microarray analysis (N=6) 
had RINs between 7.9 and 9.0 with an average RIN of 8.5. cRNA was generated and 
hybridized to IlluminaHT-12 v3 BeadChips (48,803 probes). Expression data were extracted 
with GenomeStudio (Illumina); genes with undetectable expression were excluded from 
analysis. The lumi package[14] in bioconductor was used to transform (variance-stabilizing) 
and normalize (robust spline) raw expression data. Genes significantly modulated across 
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SAHA doses were identified using a likelihood ratio test in the R package Isogene GX[15]. 
The familywise error rate was controlled using Bonferroni-adjusted p-values (p < 0.05). A 
subset of SAHA dose-responsive genes was identified and used in all subsequent analyses; 
included genes had consistent trends of up or downregulation across each increasing SAHA 
dose, and greater than 2-fold change in expression when comparing the highest dose (10 
μM) to DMSO-treated controls. Unless specified, all analyses were corrected for multiple 
comparisons using the Benjamini-Hochberg method[16] with an FDR-corrected p-value ≤ 
0.05 considered significant. Gene expression data are available at the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/): accession number GSE66994.
 Gene ontology (GO), pathway, and protein interaction network analysis
GO terms significantly over-represented for SAHA dose-responsive genes were identified 
using the BiNGO plugin for Cytoscape[17]. KEGG and BIOCARTA biological pathways 
significantly over-represented for SAHA dose-responsive genes were identified and 
characterized with DAVID[18, 19]. A direct protein interaction network (PIN) using a 
database of literature-curated protein-protein and protein-DNA interactions was constructed 
for SAHA dose-responsive genes using Metacore (Thomson Reuters).
 Real-Time Quantitative PCR (RT-qPCR)
Microarray expression data was confirmed by RT-qPCR for the top SAHA dose-responsive 
gene in samples (5 SAHA treatments in each of 6 donors), as described previously[13]. 
Briefly, RNA was reverse transcribed using qScript™ cDNA SuperMix (Quanta 
Biosciences). Expression was confirmed for the 3 most upregulated (CTNNAL1, H1F0, 
IRGM) and 3 most downregulated (DPEP2, PHF15, SELL) SAHA dose-responsive genes 
(Supplemental Table 1) with TaqMan® assays according to manufacturer protocols 
(TaqMan® Universal Master Mix II, ABI Prism 7900HT; Life Technologies). Expression 
data were normalized to RPL27; a gene previously determined to be non-responsive to 
SAHA[13]. The 2−ΔΔCt method[20] was used to determine fold change SAHA treated 
samples.
 Chromatin Immunoprecipitation (ChIP)
Three additional donors were recruited for ChIP analysis of SAHA-induced histone 
modifications. CD4+ T cells were isolated and treated with SAHA as described above. 
Chromatin was isolated and processed using ChIP-IT High Sensitivity kits (Active Motif) 
according to manufacturer’s instructions, except as noted. DNA was cross-linked to protein 
by a 5-minute incubation in fresh 1% formaldehyde and sheared to an average size of 500–
1500 base pairs by sonication in 0.1% SDS lysis buffer (Covaris M220 Sonicator; 6 minutes, 
6% duty factor, 200 counts per burst, 75 watts). DNA complexes were immunoprecipitated 
with ChIP-grade antibodies directed against total histone H3 (H3), acetylated-H3 Lysine 9 
(H3K9a), acetylated-total histone H4 (H4a), methylated-H3K4 (H3K4m), methylated-
H3K27 (H3K27m), and RNA polymerase II (Pol II). Following cross-link reversal and DNA 
purification, RT-qPCR was conducted using primers and probes (Supplemental Table 1) 
designed to span regions where histone modifications are known to occur; these regions 
were identified using the UCSC Genome Browser histone track (http://genome.ucsc.edu/)
[21]. Chromatin concentration was normalized to non-IP input control chromatin, and then 
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histone acetylation or methylation for 6 SAHA dose-responsive test genes (CTNNAL1, 
DPEP2, H1F0, IRGM, PHF15, SELL) was normalized to total H3. The 2−ΔΔCt method was 
used to calculate enrichment of histone modifications; this value was log2 transformed for 
plotting. The significance of SAHA-modulated changes in histone modification was 
determined with a one-tailed, paired t-test (p ≤ 0.05). For each SAHA dose, RNA was 
isolated from treated donor samples for RT-qPCR validation of SAHA dose-responsiveness 
in test genes, as described above.
 Predicted transcription factor binding site analysis
The DiRE web server (http://dire.dcode.org) was used to identify transcription factor binding 
sites enriched in SAHA-modulated genes[22]. Predicted key transcription factors were 
ranked by an “importance” score reflecting a transcription factor’s association with genes 
that are co-expressed following treatment, as well as its occurrence in candidate regulatory 
elements. Predicted transcription factors with an importance score ≥ 0.1 were incorporated 
into protein networks with SAHA-modulated genes, as described above.
 Results
 SAHA dose-response genes
To examine the effect of SAHA on host function in CD4+ T-cells, we utilized microarray 
analysis to identify 3,477 genes with a SAHA dose-responsive trend. This set was filtered to 
retain only genes with a fold change ≥ 2 or ≤ −2 and a consistent trend in expression across 
each increasing SAHA dose. This filter identified 1,382 genes (Supplemental Table 2) 
whose expression was consistently responsive to dose, of which 657 were upregulated and 
725 downregulated. This higher confidence subset was used in all analyses of SAHA 
modulated gene expression, and is referred to hereafter as “dose-responsive genes”.
Our previous study in primary CD4+ T cells exposed to 0.34 μM SAHA for 24 hours 
identified 1,847 differentially expressed genes[13]. Only 29% of these genes were found to 
be dose-responsive across the concentration range of SAHA used in this study. This suggests 
that not all differentially expressed genes at this low dose of SAHA are truly dose-
responsive, indicating the risks of relying on a single dose to identify gene expression 
biomarkers for SAHA response.
RT-qPCR analysis of microarray samples (Figure 1) confirmed dose-responsive changes in 
expression and consistent trends of up or downregulation in all six test genes across each 
tested SAHA dose. These genes represent gene expression biomarkers of SAHA, which are 
relevant over the concentration range examined here (0.34 to 10 μM).
 SAHA dose-responsive genes associated with HIV replication
Literature-based searches identified host dose-responsive genes with prior evidence of 
involvement in HIV activation or replication. A number of SAHA dose-responsive genes 
(summarized in Table 1) have functions relating to histone methylation, transcription, HIV 
restriction, HIV protein interaction and cell surface receptors, which on the whole likely 
enhance HIV activation.
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 GO and pathway analysis of SAHA dose-responsive genes
GO terms for biological processes related to T-cell activation, apoptosis, and chromatin 
organization were significantly over-represented (Supplemental Figure 1). Repeated analysis 
using only SAHA-upregulated dose-responsive genes primarily retained GO terms related to 
chromatin organization (Supplemental Figure 2). In contrast, analysis using only 
downregulated genes identified terms related to T-cell activation and apoptosis 
(Supplemental Figure 3). Pathway mapping of dose-responsive genes identified significant 
pathways only in downregulated genes (FDR q-value < 0.05)[23]; In downregulated genes, 
significant KEGG and BIOCARTA pathways were focused on T-cell receptor signaling, 
apoptosis, and cytotoxic T-lymphocyte mediated immune response (Table 2). Further 
analysis of expression patterns for genes associated with the T-cell receptor signaling 
pathway (KEGG) suggests a possible SAHA-induced net decrease in T-cell activation 
(Supplemental Figure 4). There was no consistent trend in apoptosis-related gene 
expression, so the net effect of SAHA on apoptosis could not be predicted (data not shown). 
This is consistent with previous results showing no cytopathic effects from SAHA-induced 
HIV reactivation[24].
 SAHA-induced histone modification
We conducted ChIP-RT-qPCR assays in primary CD4+ T cells to determine whether 
histones were hyperacetylated (H3K9a and H4a) as a consequence of SAHA treatment. 
Having identified numerous SAHA-modulated histone methyltransferases (HMTs, Table 1), 
ChIP-RT-qPCR also examined histone methylation associated with gene activation (H3K4m) 
and repression (H3K27m). H3K4-methylation was selected because 5 of 11 HMTs 
modulated by SAHA are known to methylate this site[25–29]. The most strongly 
upregulated HMT, EZH2, methylates H3K27, causing transcriptional repression[30]. 
Histone modifications were studied in the three most upregulated genes and three most 
downregulated genes. Expression of these genes was confirmed in ChIP donor samples, 
demonstrating expression patterns similar to previously tested microarray samples (Figure 
1).
Histone markers of transcriptional activation (H3K9a, H4a, and H3K4m) were consistently 
enriched, often attaining significance in the three SAHA-upregulated genes (Figure 2a). 
Unexpectedly, histone acetylation was also detected in 2 of 3 SAHA-downregulated genes, 
DPEP2 and SELL (Figure 2b). H3K4-methylation was not significantly different from 
vehicle in any of the downregulated genes. Trends in pol II enrichment were generally 
consistent with the known patterns of expression for these genes; however, significance was 
reached only for IRGM (increased pol II, SAHA-upregulated) and PHF15 (decreased pol II, 
SAHA-downregulated). H3K27-methylation was not correlated with SAHA-modulated gene 
expression. The enrichment patterns of histone modifications associated with transcriptional 
activation were consistent with gene upregulation, but did not explain SAHA-induced gene 
downregulation.
 SAHA dose-responsive transcription factor modulation
A direct protein interaction network (Supplemental Figure 5) containing SAHA dose-
responsive genes identified key hubs through which SAHA may influence expression of 
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additional genes; as summarized in Table 3. The most connected hub in the protein network 
was the transcription factor, c-Myc. Other large hubs were mostly downregulated and 
corresponded to transcription factors or coactivators (C/EBPbeta, p300, ETS1 and STAT1). 
Several of these hubs (e.g., c-Myc, EZH2, and CDK2) were also among the most connected 
hubs in our previous study summarizing differential expression in primary CD4+ T cells 
treated with 0.34 μM SAHA[13].
We also explored the possibility that SAHA might modulate activity of transcription factors 
through other mechanisms (e.g., transcription factor acetylation). Candidate transcription 
factors were identified among SAHA-responsive genes using DiRE[22], to find enrichment 
in consensus transcription factor binding sites within regulatory elements of co-expressed 
genes. Transcription factor analysis identified 13 total candidate transcription factors among 
SAHA dose-responsive genes: 8 among upregulated and 5 among downregulated genes. The 
highest confidence predictions are shown in Supplemental Figure 6. SAHA treatment 
decreased expression of three predicted transcription factors (ETS1, STAT6, and the RUNX1 
component of Core Binding Factor) with enrichment for consensus binding sites in 
downregulated genes; all three were hubs in the PIN of SAHA-modulated genes. 
Furthermore, when SAHA-non-responsive, DiRE-predicted transcription factors were 
analyzed for interactions with SAHA dose-responsive genes, the resulting PIN had SP1, 
TAL1, and MYOD emerging as major hubs; with curated evidence of acting on 156, 35, and 
30 SAHA-modulated proteins, respectively (Table 3).
 Discussion
This study revealed large numbers of genes modulated by SAHA in a dose-dependent 
manner in primary CD4+ T cells. Six of the most dose-responsive genes were validated by 
RT-qPCR (CTNNALI, DPEP, H1F0, IRGM, PHF15, SELL), suggesting they could be 
useful in vivo biomarkers for monitoring SAHA activity in current (NCT02475915, 
NCT02336074 and NCT01249443) and future clinical trials, as well as in trials of other 
HDACis such as romidepsin and panobinostat (NCT01933594 and NCT01680094). 
Encouragingly, the SAHA gene expression biomarkers PH15 and H1F0 identified in this 
study appear to have broad applicability for other compartments and cell types (e.g., whole 
blood and PBMCs), in other species (e.g., mouse and rhesus macaques), and for other 
HDACis (e.g., panobinostat) (Drs. Richard Barnard and Bonnie Howell, Merck Inc., 
personal communication).
Acetylation of histones only partially explains the effects of SAHA on host cell gene 
expression [31–34]. ChIP-RT-qPCR based evaluation of histone modifications in the six 
most SAHA-dose responsive genes (Figure 2) demonstrated that increased histone 
acetylation was generally observed regardless of gene up or downregulation. The PIN of 
SAHA-modulated genes revealed several transcription factors that were major hubs (Table 
3). Therefore, by altering expression or activity of transcription factors, it is plausible that 
SAHA influences secondary effects (including downregulation) on scores of other genes.
This study identified several SAHA dose-responsive host genes that may contribute to 
SAHA’s ability to facilitate HIV activation (Table 1). With respect to enhancing HIV 
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activation, the protein products of IRGM and HSP70 have demonstrated direct interactions 
with HIV proteins to promote viral replication[35, 36] and were strongly upregulated by 
SAHA. Furthermore, several HIV restriction factors, APOBEC3G, APOBEC3F, EV12B and 
TRIM22[37] were downregulated in a dose-dependent manner by SAHA. Downregulation 
of MYC, the most connected hub in our PIN, is likely to be an important contributor to HIV 
activation by SAHA, as we have reported previously[13]. The transcription factor SP1 had 
predicted binding sites in a large proportion of upregulated genes and was a major hub when 
combined in a PIN with SAHA-modulated genes. Although no change in SP1 expression 
was detected, HDACi treatment can acetylate the SP1 protein, enhancing its ability to bind 
the HIV LTR and promote viral transcription[11]. Thus, SAHA may alter SP1 activity by 
direct acetylation without changing its expression, contributing to HIV activation. In 
contrast, with respect to repressing HIV activation, several transcription factors (ETS1, 
CEBPB, LEF1) shown to bind the HIV LTR and activate HIV transcription[38–40] were 
downregulated by SAHA. Furthermore, two cell surface molecules (CCL5/RANTES and 
ITGAL/CD11a) downregulated by SAHA are thought to enhance cell-to-cell transmission of 
the activated virus [41–43]. Finally, a number of histone methyltransferases were modulated 
by SAHA with half being upregulated and half downregulated (Table 1). This represents a 
heterogenous signal with respect to HIV activation where broad and specific 
methyltransferase inhibitors have been shown to activate HIV from latency [44, 45]. These 
observations support recent findings from the gene expression analysis of samples from 
clinical trials with SAHA suggesting that multiple mechanisms may contribute to HIV 
activation[7]. Beyond the ability to directly activate HIV through the relaxation of 
chromatin, SAHA may operate through indirect mechanisms by modulating host genes some 
of which appear to have positive and others negative roles with respect to HIV activation. 
For the majority of the genes listed in Table 1, SAHA induced changes in expression would 
likely favor HIV activation from latency. However, recent evidence suggests that HIV 
activation from latency may also require removal of an as yet unknown post-transcriptional 
block[46]; no obvious candidates for such an activity emerged from our results.
Analysis of functional categories and pathways associated with SAHA-modulated genes 
revealed categories related to T-cell activation and suggested possible downregulation of T-
cell receptor activation. Several studies implicate T-cell activation as an essential component 
for efficient HIV infection and replication. Possible consequences of SAHA impeding T-cell 
activation may include decreased HIV transcription and translation, which may diminish 
eradication of infected cells during ART. This is consistent with a recent study in a primary 
CD4+ T cell latency model showing that SAHA treatment resulted in only a modest increase 
in HIV protein despite a 3-fold increase in HIV transcription[46]. Our data suggest that T-
cell receptor activation may require particular scrutiny when evaluating dosing regimens for 
SAHA, or future analogues with increased bioavailability or potency.
The possible utilization of SAHA to activate latent HIV is still being evaluated in clinical 
trials, so it is too early to know whether it will have a key role in a shock and kill approach 
to an HIV cure. In the event that SAHA does not show the desired efficacy on its own, it 
may still be used as part of a combination therapy with other latency activating compounds. 
Our results indicated plausible alternative mechanisms of action for SAHA that may help to 
identify additional therapies or adjuvants that can be used to maximize the effectiveness of a 
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cure strategy. This current study was focused on gene expression in primary resting CD4+ T 
cells because these cells are considered the primary reservoir of latent HIV infection in the 
peripheral blood. Future work will profile the effects of SAHA and other latency reversing 
agents in PBMCs, as well as other cell subsets and tissues to further elucidate the effects of 
SAHA.
In summary, the primary outcome of this work was the identification of gene expression 
biomarkers of SAHA administration (CTNNALI, DPEP, H1F0, IRGM, PHF15, SELL). 
These results further indicated other possible mechanisms through which SAHA may affect 
activation of HIV from latency. Our data suggest that SAHA alters host gene expression 
through the combined action of multiple mechanisms, including histone acetylation, histone 
methylation, and altered expression and possible acetylation of transcription factors. These 
results may be used to identify targets for future knockdown or overexpression studies using 
in vitro HIV latency models to determine the contribution of host genes to the SAHA-
induced activation of HIV.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RT-qPCR confirmation of SAHA dose-responsive gene expression
Gene expression changes induced by SAHA were confirmed by RT-qPCR in the same RNA 
samples used for microarray analysis (Donors 1–6). RT-qPCR analysis was also used to 
confirm expression changes for the six most strongly SAHA dose-responsive genes in 
primary CD4+ T cells used in ChIP analysis (Donors 7–9). (a) The top 3 dose-responsive 
upregulated genes, and (b) the top 3 dose-responsive downregulated genes. Abbreviations 
are as follows: CTNNAL1, catenin (cadherin-associated protein), alpha-like 1; H1f0, H1 
histone family, member 0; IRGM, immunity-related GTPase family, M; DPEP2, Dipeptidase 
2; PHF15, PHD finger protein 15; SELL, Selectin L
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Figure 2. ChIP-RT-qPCR analysis of histone modifications for the top six genes SAHA dose-
responsive genes
Histone modifications and Pol II occupancy were examined in the promoters of the (a) 3 
most upregulated (CTNNAL1, H1F0, IRGM) and (b) 3 most downregulated (DPEP2, 
PHF15, SELL) SAHA dose-responsive genes when comparing a SAHA treatment of 10μM 
to vehicle. Fold enrichment of immunoprecipitated chromatin upon SAHA treatment is 
plotted on the log2 scale with error bars representing the standard error of the mean. 
Significant enrichment was assessed in a paired t-test and reported at the 0.1 (*) and 0.05 
(**) cut-offs. Abbreviations are as follows: H3K9a, acetylated H3 Lysine 9; H4a, acetylated 
total Histone H4; H3K4m, methylated H3K4; H3K27m, methylated H3K27; Pol II, RNA 
polymerase II.
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Table 1
SAHA dose-responsive genes with potential roles in HIV activation or replication1.
Category Gene Maximum fold change (10 μM SAHA)




HIV protein interactors IRGM 34.3
HSP70 (HSPA2) 7.7















Cell surface molecules CCL5 (RANTES) −15.6
CD11a (ITGAL) −13.1
1
Fold change was calculated by comparing expression between the 10 μM dose of SAHA and the untreated control.
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Table 2
Pathway categories significantly enriched (q-value ≤ 0.05) for SAHA dose-responsive genes.
Category Pathway1 Genes q-value2
T cell receptor signaling/
activation
Lck and Fyn tyrosine kinases in initiation of TCR 
activation (BIOCARTA)
CD3D, CD3E, LCK, CD247, ZAP70, 
CD4
2.38E-04
Activation of Csk Inhibits Signaling through TCR 
(BIOCARTA)
CD3D, CD3E, LCK, CD247, ZAP70, 
CD4
1.12E-03
T-Cell Receptor Signaling Pathway (KEGG) PTPN6, CARD11, CD3D, CD3E, 
CD40LG, MAPK13, LCK, CD247, 
ZAP70, CD4, CD28
3.38E-03
The Co-Stimulatory Signal During T-Cell Activation CD3D, CD3E, LCK, CD247, ITGB2 1.44E-02
T-Cell Receptor and CD3 Complex CD3D, CD3E, CD247 3.69E-02
Role of Tob in T-Cell Activation CD3D, CD3E, CD247, CD28 4.55E-02
Apoptosis HIV Induced T-Cell Apoptosis (BIOCARTA) CD3D, CD3E, CD247, CD4, CD28 1.30E-03
Cytotoxic T cell function T-Cytotoxic Cell Surface Molecules (BIOCARTA) ITGAL, CD3D, CD3E, CD247, 
ITGB2, CD28
2.66E-04
CTL Mediated Immune Response Against Target 
Cells (BIOCARTA)
ITGAL, CD3D, CD3E, CD247, 
ITGB2
5.31E-03
Cell surface molecules T-Helper Cell Surface Molecules (BIOCARTA) ITGAL, CD3D, CD3E, CD247, 
ITGB2, CD4, CD28
2.36E-05
Adhesion Molecules on Lymphocyte (BIOCARTA) ITGAL, CD44, SELL, ITGB2, 
ITGA4
1.30E-03
Monocyte and its Surface Molecules (BIOCARTA) ITGAL, CD44, SELL, ITGB2, 
ITGA4
2.18E-03
Neutrophil and its Surface Molecules (BIOCARTA) ITGAL, CD44, SELL, ITGB2 1.10E-02
Cell Adhesion Molecules (BIOCARTA) ITGAL, CD40LG, SELL, ICAM3, 
NLGN2, ITGB2, CD4, ITGA4, 
CD226, CD28
2.85E-02




Pathways identified with DAVID v6.7; analysis utilized curated pathway databases KEGG and BIOCARTA.
2
q-value: FDR-adjusted p-value (Storey, 2003).
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Table 3
Major hubs (>20 edges) in the protein interaction network of SAHA dose-responsive genes combined with 
transcription factors predicted to bind in the promoters of SAHA modulated genes.
Protein Hub # Edges Function Response to SAHA
c-Myc 294 Transcription Factor Downregulated
SP1* 156 Transcription Factor N/A**
p300 94 Histone Acetyl Transferase Downregulated
C/EBPbeta 63 Transcription Factor Downregulated
EZH2 60 Histone Methyl Transferase Upregulated
STAT1 53 Transcription Factor Upregulated
CBP 49 Generic Enzyme Downregulated
p21 48 Binding Protein Upregulated
SP3 44 Transcription Factor Downregulated
ETS1* 42 Transcription Factor Downregulated
AML1 (RUNX1) * 41 Transcription Factor Downregulated
CDK2 40 Protein Kinase Downregulated
SMAD3 35 Transcription Factor Upregulated
TAL1* 35 Transcription Factor N/A**
Lck 33 Protein Kinase Downregulated
MYOD* 32 Transcription Factor N/A**
Bcl-2 30 Binding Protein Downregulated
ZAP70 30 Protein Kinase Downregulated
Caspase-1 28 Protease Downregulated
STAT6* 28 Transcription Factor Downregulated
HDAC3 27 Histone Deacetylase Upregulated
ATM 26 Protein Kinase Downregulated
SHP-1 23 Protein Phosphatase Downregulated
Lef-1 22 Transcription Factor Downregulated
E2F3 21 Transcription Factor Downregulated
*
Predicted transcription factors (DiRE, http://dire.dcode.org)
**
Expression not modulated by SAHA
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